- Home
- SLGL vs TENX Comparison
SLGL vs TENX Comparison
Compare SLGL & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- TENX
- Stock Information
- Founded
- SLGL 1997
- TENX 1967
- Country
- SLGL Israel
- TENX United States
- Employees
- SLGL N/A
- TENX N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- TENX Health Care
- Exchange
- SLGL Nasdaq
- TENX Nasdaq
- Market Cap
- SLGL 19.3M
- TENX 21.6M
- IPO Year
- SLGL 2018
- TENX N/A
- Fundamental
- Price
- SLGL $8.14
- TENX $5.83
- Analyst Decision
- SLGL Buy
- TENX Strong Buy
- Analyst Count
- SLGL 1
- TENX 3
- Target Price
- SLGL $40.00
- TENX $16.00
- AVG Volume (30 Days)
- SLGL 25.4K
- TENX 41.0K
- Earning Date
- SLGL 08-15-2025
- TENX 08-12-2025
- Dividend Yield
- SLGL N/A
- TENX N/A
- EPS Growth
- SLGL N/A
- TENX N/A
- EPS
- SLGL N/A
- TENX N/A
- Revenue
- SLGL $12,103,000.00
- TENX N/A
- Revenue This Year
- SLGL N/A
- TENX N/A
- Revenue Next Year
- SLGL $31.17
- TENX N/A
- P/E Ratio
- SLGL N/A
- TENX N/A
- Revenue Growth
- SLGL 603.66
- TENX N/A
- 52 Week Low
- SLGL $3.34
- TENX $2.80
- 52 Week High
- SLGL $16.50
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- SLGL 63.80
- TENX 50.54
- Support Level
- SLGL $6.96
- TENX $5.68
- Resistance Level
- SLGL $7.48
- TENX $5.98
- Average True Range (ATR)
- SLGL 0.28
- TENX 0.39
- MACD
- SLGL 0.07
- TENX 0.00
- Stochastic Oscillator
- SLGL 95.88
- TENX 18.87
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.